Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EOLS
HOLDEvolus, Inc. · Healthcare · United States · $394M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Evolus, Inc. is a medical aesthetics company dedicated to developing and commercializing innovative neurotoxins and dermal fillers. The company's flagship product, Jeuveau® (known as Nuceiva® in certain international markets), is a botulinum toxin type A designed for the temporary improvement of moderate to severe frown lines. It distinguishes itself through a focused commercial strategy and competitive product profile, aiming to capture significant market share in the rapidly growing global aesthetics market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.6M | 202.1M | 266.3M | 297.2M | 26.0% | 301.8M | 330.5M | 387.7M | 14.2% |
| EPS | -1.33 | -1.08 | -0.81 | -0.80 | — | -0.64 | — | — | — |
| Shares | 56.3M | 57.8M | 63.5M | 65.0M | +15.5% | 65.9M | — | — | — |
| Debt | 74.4M | 126.5M | 130.0M | 155.0M | 27.7% | 164.9M | — | — | — |
| Equity | 18.5M | -20.7M | 5.5M | -23.1M | -45.4% | — | — | — | — |
| Op CF | -84.9M | -34.0M | -18.0M | -42.3M | — | -36.6M | — | — | — |
| Inv CF | -2.9M | -1.6M | -4.8M | -8.5M | — | — | — | — | — |
| Fin CF | -4.1M | 44.6M | 47.4M | 17.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EOLS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EOLS | Evolus, Inc.(you) | $394M | 39 | HOLD |
| ORGO | Organogenesis Holdings Inc. | $308M | 39 | HOLD |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| AKBA | Akebia Therapeutics, Inc. | $327M | 33 | SELL |
| TKNO | Alpha Teknova, Inc. | $266M | 36 | HOLD |
| GLAS | Glass House Brands Inc. | $899M | 35 | HOLD |
| ESPR | Esperion Therapeutics, Inc. | $817M | 33 | SELL |
| AQST | Aquestive Therapeutics, Inc. | $462M | 18 | STRONG SELL |
| CL.CN | Cresco Labs Inc. | $263M | 57 | HOLD |
| GRIN.CN | Grown Rogue International Inc. | $109M | 39 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%